NEWS SNIPPETS

2-deoxy-D-glucose (2-DG)

  • It is an anti-COVID-19 drug, indigenously developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS) - a DRDO lab - in collaboration with Dr. Reddy’s Laboratories (DRL).
  • Clinical trials have shown that 2-DG helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
  • Drugs Controller General of India (DCGI) granted permission for emergency use of the drug as adjunct therapy in moderate to severe COVID-19 patients.
  • A generic molecule and analogue of glucose, 2-DG selectively accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis ....
Do You Want to Read More?
Subscribe Now

To get access to detailed content

Already a Member? Login here


Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.